Main menu

Responsibility

European patient group funding

Pfizer Support to European and International Patient Organisations in 2013

The EFPIA Code on Relationships between the Pharmaceutical Industry and Patient Organisations came into force across Europe on 1st July 2008. Pfizer has been at the forefront of industry transparency efforts and we fully support the Code and its aims of enhancing transparency and ensuring that relationships between the pharmaceutical industry and patient organisations take place in the most open and ethical manner, in full recognition of the independence of patient organisations.

Financial support, such as through educational grants to support -giving full independence - an organisation's core activities or for specific projects, only forms one aspect of our relationship with patient organisations. Increasingly, we are building relationships with patient organisations who are interested in working collaboratively with us to find new solutions to old problems. We are proud to work with many patient organisations, including those listed below, and our partnerships are open and transparent. These are 2-way relationships – we learn from each other, and our common viewpoint is that healthcare, to be effective, should be patient-centred.

The links below contain information on the support Pfizer has provided to National, European-level and international patient organisations in 2013. It follows the standards set out in the EFPIA code of practice governing relationships between the pharmaceutical industry and patient associations. Information to European-level and International patient organisations relevant to other countries is cross-referenced. Information on support to national patient organisations can be found via the following links to local Pfizer organisations in respective European countries:

European-Level Organisations (PDF)
Austria (PDF)
Belgium (Flemish Language) (French Language) (PDF)
Bulgaria (PDF)
Czech Republic (PDF)
Croatia (PDF)
Cyprus (No funding provided to patient organizations in 2013)
Denmark (PDF)
Estonia (PDF)
Finland (PDF)
France (PDF)
Germany (PDF)
Greece (PDF)
Hungary (PDF)
Iceland (No funding provided to patient organizations in 2013)
Ireland (PDF)
Italy (PDF)
Latvia (PDF)
Lithuania (PDF)
Malta (No funding provided to patient organisations in 2013)
Netherlands (PDF)
Norway (PDF)
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Serbia (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Switzerland
Turkey (PDF)
United Kingdom (PDF)

 

Pfizer Support to European and International Patient Organisations in 2012

The EFPIA Code on Relationships between the Pharmaceutical Industry and Patient Organisations came into force across Europe on 1st July 2008. Pfizer has been at the forefront of industry transparency efforts and we fully support the Code and its aims of enhancing transparency and ensuring that relationships between the pharmaceutical industry and patient organisations take place in the most open and ethical manner, in full recognition of the independence of patient organisations.

Financial support, such as through educational grants to support -giving full independence - an organisation's core activities or for specific projects, only forms one aspect of our relationship with patient organisations. Increasingly, we are building relationships with patient organisations who are interested in working collaboratively with us to find new solutions to old problems. We are proud to work with many patient organisations, including those listed below, and our partnerships are open and transparent. These are 2-way relationships – we learn from each other, and our common viewpoint is that healthcare, to be effective, should be patient-centred.

The links below contain information on the support Pfizer has provided to National, European-level and international patient organisations in 2011. It follows the standards set out in the EFPIA code of practice governing relationships between the pharmaceutical industry and patient associations. Information to European-level and International patient organisations relevant to other countries is cross-referenced. Information on support to national patient organisations can be found via the following links to local Pfizer organisations in respective European countries:

European & International (PDF)
Austria (PDF)
Belgium and Luxemburg(PDF)
Bulgaria (PDF)
Czech Republic (PDF)
Croatia (PDF)
Denmark (PDF)
Estonia (PDF)
Finland (PDF)
France (PDF)
Germany (PDF)
Greece and Cyprus (PDF)
Hungary (PDF)
Iceland (PDF)
Ireland (PDF)
Italy (PDF)
Latvia (PDF)
Lithuania (PDF)
Malta (No funding provided to patient organisations in 2012)
Netherlands (PDF)
Norway (PDF)
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Serbia (No funding provided to patient organisations in 2012)
Slovakia (PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Switzerland
Turkey (No funding provided to patient organisations in 2012)
United Kingdom (PDF)
 

 

Pfizer Support to European and International Patient Organisations in 2011

The EFPIA Code on Relationships between the Pharmaceutical Industry and Patient Organisations came into force across Europe on 1st July 2008. Pfizer has been at the forefront of industry transparency efforts and we fully support the Code and its aims of enhancing transparency and ensuring that relationships between the pharmaceutical industry and patient organisations take place in the most open and ethical manner, in full recognition of the independence of patient organisations.

Financial support, such as through educational grants to support -giving full independence - an organisation's core activities or for specific projects, only forms one aspect of our relationship with patient organisations. Increasingly, we are building relationships with patient organisations who are interested in working collaboratively with us to find new solutions to old problems. We are proud to work with many patient organisations, including those listed below, and our partnerships are open and transparent. These are 2-way relationships – we learn from each other, and our common viewpoint is that healthcare, to be effective, should be patient-centred.

The links below contain information on the support Pfizer has provided to National, European-level and international patient organisations in 2011. It follows the standards set out in the EFPIA code of practice governing relationships between the pharmaceutical industry and patient associations. Information to European-level and International patient organisations relevant to other countries is cross-referenced. Information on support to national patient organisations can be found via the following links to local Pfizer organisations in respective European countries:

European & International (PDF)
Austria (PDF)
Belgium and Luxemburg(PDF)
Bulgaria (PDF)
Czech Republic (PDF)
Croatia (PDF)
Denmark (PDF)
Estonia (PDF)
Finland (PDF)
France (PDF)
Greece and Cyprus (PDF)
Hungary (PDF)
Iceland (No funding provided to patient organisations in 2011)
Ireland (PDF)
Italy (PDF)
Latvia (No funding provided to patient organisations in 2011)
Lithuania (PDF)
Malta (No funding provided to patient organisations in 2012)
Netherlands (PDF)
Norway (PDF)
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Switzerland
Turkey (No funding provided to patient organisations in 2011)
United Kingdom (PDF)

 

Pfizer Support to European and International Patient Organisations in 2010

The EFPIA Code on Relationships between the Pharmaceutical Industry and Patient Organisations came into force across Europe on 1st July 2008. Pfizer has been at the forefront of industry transparency efforts and we fully support the Code and its aims of enhancing transparency and ensuring that relationships between the pharmaceutical industry and patient organisations take place in the most open and ethical manner, in full recognition of the independence of patient organisations.

Financial support, such as through educational grants to support -giving full independence - an organisation's core activities or for specific projects, only forms one aspect of our relationship with patient organisations. Increasingly, we are building relationships with patient organisations who are interested in working collaboratively with us to find new solutions to old problems. We are proud to work with many patient organisations, including those listed below, and our partnerships are open and transparent. These are 2-way relationships – we learn from each other, and our common viewpoint is that healthcare, to be effective, should be patient-centred.

The links below contain information on the support Pfizer has provided to National, European-level and international patient organisations in 2010. It follows the standards set out in the EFPIA code of practice governing relationships between the pharmaceutical industry and patient associations. Information to European-level and International patient organisations relevant to other countries is cross-referenced. Information on support to national patient organisations can be found via the following links to local Pfizer organisations in respective European countries:

European & International (PDF)
Austria (PDF)
Belgium and Luxemburg(PDF)
Bulgaria (PDF)
Croatia (PDF)
Denmark (PDF)
Estonia (No funding provided to patient organisations in 2010)
Finland (PDF)
France (PDF)
Germany (PDF)
Greece and Cyprus (PDF)
Hungary (PDF)
Iceland (No funding provided to patient organisations in 2010)
Ireland
Italy (PDF)
Latvia (No funding provided to patient organisations in 2010)
Lithuania (PDF)
Malta (No funding provided to patient organisations in 2010)
Netherlands (PDF)
Norway (PDF)
Portugal (PDF)
Romania (PDF)
Slovakia (PDF)
Spain (PDF)
Sweden
Switzerland
United Kingdom (PDF)